



FOR IMMEDIATE RELEASE

Contact: Holly P. Glass  
[Holly.glass@semprusbio.com](mailto:Holly.glass@semprusbio.com)  
703.754.2848

**SEMPRUS BIOSCIENCES APPOINTS NEW PROCESS ENGINEERING EXECUTIVE**  
*Douglas Weaver Named Group Leader, Process Development*

**Cambridge, MA** (September 8, 2010)—Semprus BioSciences, Corp., today announced the appointment of Douglas Weaver to the new position of Group Leader, Process Development, effective immediately. In this role, Doug will spearhead the company’s effort to complete the development of manufacturing processes and scale up of Semprus’ proprietary vascular access product platform. This line features the company’s long acting Semprus Sustain™ Performance, the first non-leaching single surface modification that simultaneously reduces bacterial growth and thrombus formation (blood clots) on medical devices with multi-month efficacy.

Doug is an experienced and versatile leader with twenty-five years’ experience in medical device and bulk pharmaceutical product and process development. He is a recognized subject matter expert for design controls, risk management and Six Sigma methods applied to the design and development of commercial products.

Since 2004, Doug served as Principal Engineer for Design Assurance and Supplier Compliance at Boston Scientific Corporation (BSC). Prior to joining BSC, Doug held senior development posts at Genzyme Biosurgery, Inc., and Focal, Inc., the former synthetic surgical sealant manufacturer which was acquired by Genzyme. At Focal, Doug was instrumental in leading the development of GMP compliant manufacturing processes while driving the scale-up and commercialization of the company’s core polymer technology.

“Doug’s expertise in design control and process development combined with his ability to lead highly skilled teams across multiple facilities make him the perfect fit for Semprus BioSciences,” said Semprus Chief Executive Officer David L. Lucchino. “He is a great asset to our expanding world class team, and we look forward to his guidance and insight moving forward as we drive towards commercialization.”

Doug holds a Masters of Business Administration from National University, San Diego, CA, and earned his Bachelor of Arts in Chemical Technology from Metropolitan State University, Minneapolis, MN. He is a certified Six Sigma Green Belt and a HAZOPs Incident Commander.

Semprus BioSciences is a venture-backed biomedical company which spun out of the labs of famed MIT researcher Dr. Robert Langer in 2007. Semprus’ dual mission is to provide biofilm-free medical devices designed to preserve patients’ long-term health and quality-of-life and to contribute to health care cost efficiencies. Visit [www.semprusbio.com](http://www.semprusbio.com) for additional information.